PATH to use Liquidia particle technology for malaria

The PATH Malaria Vaccine Initiative (MVI) will have use of Liquidia Technologies' PRINT particle technology for its research into new, more effective malaria vaccines. The technology helps researchers control the size, shape and chemistry of protein particles used in the malaria vaccine.

"MVI is actively working to identify second generation vaccine approaches with the potential to elicit higher levels of efficacy over a longer period of time; approaches that could target the disease as well as parasite transmission, which will be important in the fight to control and eliminate malaria," said Ashley Birkett, director of Pre- and Early Clinical Research and Development at MVI, in a statement. "The PRINT technology represents an advancement in the controlled delivery of vaccine components, which may enhance efficacy and safety by bringing together multiple technologies necessary to achieve a next-generation malaria vaccine."

- see the Liquidia release

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.